|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/137 | (2006.01) |
| A61P 29/02 | (2018.01) | ||
| A61P 3/02 | (2006.01) | ||
| A61K 31/137 | (2013.01) | ||
| A61P 21/00 | (2006.01) | ||
| A61P 25/00 | (2018.01) | ||
| A61P 25/00 | (2006.01) | ||
| A61P 21/00 | (2018.01) | ||
| A61P 29/02 | (2006.01) |
| (11) | Number of the document | 4101445 |
| (13) | Kind of document | T |
| (96) | European patent application number | 21750441.4 |
| Date of filing the European patent application | 2021-02-05 | |
| (97) | Date of publication of the European application | 2022-12-14 |
| (45) | Date of publication and mention of the grant of the patent | 2025-04-30 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/JP2021/004216 |
| Date | 2021-02-05 |
| (87) | Number | WO 2021/157682 |
| Date | 2021-08-12 |
| (30) | Number | Date | Country code |
| 2020019153 | 2020-02-06 | JP |
| (72) |
IZAKI, Hitoshi , JP
HAYASHI, Rikako , JP
YANAI, Yoshiari , JP
|
| (73) |
Mitsubishi Tanabe Pharma Corporation ,
3-2-10, Dosho-machi,
Chuo-ku,, Osaka-shi,
Osaka 541-8505,
JP
|
| (54) | AMISELIMOD FOR USE IN THE TREATMENT OF MYALGIC ENCEPHALOMYELITIS/CHRONIC FATIGUE SYNDROME |
| AMISELIMOD FOR USE IN THE TREATMENT OF MYALGIC ENCEPHALOMYELITIS/CHRONIC FATIGUE SYNDROME |